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A B S T R A C T
Purpose
The initial results of the APL0406 trial showed that the combination of all-trans-retinoic acid (ATRA)
and arsenic trioxide (ATO) is at least not inferior to standard ATRA and chemotherapy (CHT) in ﬁrst-
line therapy of low- or intermediate-risk acute promyelocytic leukemia (APL). We herein report the
ﬁnal analysis on the complete series of patients enrolled onto this trial.
Patients and Methods
The APL0406 study was a prospective, randomized, multicenter, open-label, phase III noninferiority
trial. Eligible patients were adults between 18 and 71 years of age with newly diagnosed, low- or
intermediate-risk APL (WBC at diagnosis # 10 3 109/L). Overall, 276 patients were randomly
assigned to receive ATRA-ATO or ATRA-CHT between October 2007 and January 2013.
Results
Of 263 patients evaluable for response to induction, 127 (100%) of 127 patients and 132 (97%) of 136
patients achieved complete remission (CR) in theATRA-ATOandATRA-CHT arms, respectively (P= .12).
After a median follow-up of 40.6 months, the event-free survival, cumulative incidence of relapse, and
overall survival at 50 months for patients in the ATRA-ATO versus ATRA-CHT arms were 97.3% v 80%,
1.9% v 13.9%, and 99.2% v 92.6%, respectively (P , .001, P = .0013, and P = .0073, respectively).
Postinduction events included two relapses and one death in CR in the ATRA-ATO arm and two in-
stances ofmolecular resistance after third consolidation, 15 relapses, and ﬁve deaths in CR in the ATRA-
CHT arm. Two patients in the ATRA-CHT arm developed a therapy-related myeloid neoplasm.
Conclusion
These results show that the advantages of ATRA-ATO over ATRA-CHT increase over time and that
there is signiﬁcantly greater and more sustained antileukemic efﬁcacy of ATO-ATRA compared with
ATRA-CHT in low- and intermediate-risk APL.
J Clin Oncol 34. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Standard therapy of acute promyelocytic leu-
kemia (APL) has long since relied on the
combination of all-trans-retinoic acid (ATRA)
and chemotherapy (CHT). Despite providing
high cure rates, this approach is associated
with frequent severe hematologic toxicity and
development of secondary myeloid neoplasms
in approximately 2% of patients.1-11 The in-
troduction of arsenic trioxide (ATO) in APL
treatment has resulted in similarly high re-
mission and survival rates coupled with sig-
niﬁcantly reduced myelosuppression. ATO is
currently regarded as the most effective single
agent in APL and is licensed for the treatment
of relapsed and refractory APL.12-15
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Recently, CHT-free regimens based on ATO with or without
ATRA have proven highly effective in newly diagnosed APL.16-19
After pilot studies suggesting that ATRA plus ATO could substitute
the standard approach in the treatment of newly diagnosed
disease,18,19 two large independent randomized trials reported
signiﬁcantly improved outcomes for patients treated with ATRA-
ATO compared with those receiving ATRA-CHT.20,21 On the basis
of these data, expert panels from the United States and Canada
have indicated ATRA-ATO as the favored option in ﬁrst-line
therapy of non–high-risk APL.22,23
The APL0406 randomized trial reported by the Gruppo
Italiano per le Malattie Ematologiche dell’Adulto (GIMEMA),
Acute Myeloid Leukemia Study Group (AMLSG), and Study Al-
liance Leukemia (SAL) showed in the initial series of 156 patients
that ATO-ATRA is at least not inferior, and probably superior, to
standard ATRA-CHT for patients with newly diagnosed, non–
high-risk APL.20 We herein report the results of this study after
a more prolonged follow-up and including the extended and ﬁnal
series of patients who were randomly assigned to receive ATRA-
ATO or ATRA-CHT.
PATIENTS AND METHODS
Study Design and Patients
The APL0406 study was a prospective, randomized, multicenter,
open-label, phase III noninferiority trial. The study was designed by
GIMEMA in April 2006 (APL0406); it was started in Italy in October 2007
and was joined in 2008 by the German SAL and AMLSG groups. The study
was designed to show that the ATRA-ATO regimen is not inferior to the
ATRA-CHT regimen in terms of event-free survival (EFS) rate at 2 years.
The full trial design and the results obtained in the initial series of 156
patients were reported in 2013.20 Brieﬂy, eligible patients were adults age
18 to 71 years with newly diagnosed, low- or intermediate-risk APL (WBC
at diagnosis # 10 3 109/L). Initial patient enrollment and random as-
signment were based on the sole morphologic diagnosis of APL according
to the French-American-British criteria. Random assignment was stratiﬁed
by institutions; random block size was four.
Genetic diagnostic conﬁrmation was mandatory for eligibility and was
carried out through centralized reference laboratories in Italy and Germany
(F.L.-C., Universita` Tor Vergata in Rome, Italy, for GIMEMA and C.T., Carl
Gustav Carus Universita¨tsklinikum in Dresden, Germany, for SAL and
AMLSG). The trial was conducted in accordance with the Declaration of
Helsinki, received institutional review board approval by all participating
centers, and was registered at ClinicalTrials.gov (identiﬁer: NCT00482833).
In September 2010, the study reached the initially programmed
accrual of 162 patients and enrollment was suspended. At the time of
inclusion of the last patient, however, compliance with quality-of-life
(QoL) questionnaires was lower than initially anticipated. Therefore,
considering QoL was a key secondary objective of the trial, the study was
amended and restarted in March 2011 in an effort to maximize in-
formation obtained regarding burden of disease and treatment effects over
time from patients themselves. The new target accrual to meet the QoL
objective was set to 276 patients. The amendment was approved by all
ethical committees of participating centers, and all patients provided
written informed consent. A list of authors and centers that contributed to
the APL0406 trial can be found in the Appendix (online only).
Treatment Arms, Supportive Measures, and Management of
Complications
The treatment schedules for the ATRA-ATO and ATRA-CHT regimens,
the recommended supportive measures to prevent and treat the APL-
associated coagulopathy and differentiation syndrome (DS), and the man-
agement of major expected therapy-related complications (QTc prolongation,
hyperleukocytosis, and hepatotoxicity) have been reported in detail.20 In
particular, prednisone prophylaxis (0.5 mg/kg daily) was administered during
the entire remission induction phase to prevent DS. Hydroxyurea was the only
cytotoxic agent allowed to control hyperleukocytosis. Finally, temporary
discontinuation and dose adjustments were recommended to manage ATO
nonhematologic toxicity, as detailed elsewhere.20
Laboratory Studies
Genetic studies, including reverse transcriptase polymerase chain re-
action (RT-PCR) ampliﬁcation of the PML-RARA hybrid using standardized
protocols, were mandatory at diagnosis and after the third consolidation for
all patients enrolled onto the study. Furthermore, longitudinal prospective
monitoring of minimal residual disease was assessed by nested RT-PCR and
quantitative RT-PCR in marrow samples for patients in both arms after
induction therapy (for investigational purposes only) and during follow-up.
Molecular studies also included fms-like tyrosine kinase 3 (FLT3) mutational
status for the presence of the internal tandem duplication.
Outcomes
The primary study objective was to compare EFS at 2 years from
diagnosis between the two treatment arms. Treatment failure was deﬁned
as any of the following events: no achievement of hematologic complete
remission (HCR) after induction therapy, no achievement of molecular
complete remission (CR) after three consolidation courses, relapse
(molecular or hematologic, whichever was detected ﬁrst), and death.
Secondary end points included rate of HCR after induction, overall
survival (OS) at 2 years, disease-free survival (DFS), cumulative incidence
of relapse (CIR, deﬁned as the time from HCR achievement to either
molecular or hematologic relapse, whichever was detected ﬁrst), incidence
and severity of hematologic and nonhematologic toxic episodes during
treatment (graded according to National Cancer Institute Common
Terminology Criteria for Adverse Events), kinetics of minimal residual
disease, and self-assessed QoL.
OS was deﬁned as the time from diagnosis to death from any cause.
DFS was deﬁned as the time from HCR achievement to relapse (either
molecular or hematologic), persistence of polymerase chain reaction (PCR)
positivity after consolidation, death, or date of last follow-up for patients
alive in ﬁrst molecular CR. Induction deathwas deﬁned as death occurring at
any time during induction therapy, before the achievement of HCR. CIRwas
calculated from the date of HCR until ﬁrst relapse (either molecular or
hematologic relapse) considering death in CR as a competing risk.
Statistical Analysis
All patients enrolled onto the study were analyzed following an intent-
to-treat principle. Characteristics of patients were summarized by cross-
tabulations (categorical variables) and quantiles (eg, median; for continuous
variables). Nonparametric tests were applied for comparisons between
groups (x2 and Fisher’s exact test for categorical variables; Mann-WhitneyU
test and Kruskal-Wallis test for continuous variables). Survival distributions
(OS, EFS, and DFS) were estimated using the Kaplan-Meier method. CIR
was calculated using the proper nonparametricmethod. Differences in terms
ofOS, EFS, andDFSwere evaluated using the log-rank test. TheGray test was
applied to compare cumulative incidence curves. All tests were two-sided.
RESULTS
Enrollment and Patient Characteristics
The enrollment period was from October 2007 to January
2013. A total of 276 patients with low- or intermediate-risk APL
were randomly assigned. Genetic tests excluded PML-RARA–
positive APL in six patients (ﬁve patients randomly assigned to
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ATRA-ATO and one randomly assigned to ATRA-CHT). Of the
remaining 270 patients, four patients did not start allocated
treatment (two treatment refusals, both in the ATRA-CHT arm,
and twomajor violations, both in the ATRA-ATO arm). Therefore,
266 patients (129 randomly assigned to ATRA-ATO and 137
randomly assigned to ATRA-CHT) were included in the intent-to-
treat analysis. The disposition of the patients and reasons for
exclusion are shown in Figure 1.
The main demographic, clinical, and laboratory features of the
266 patients eligible for analysis are listed in Table 1. There were no
signiﬁcant differences in the baseline characteristics between the two
cohorts. The present analysis was performed in December 2015 with
amedian follow-up time of 40.6months (range, 0.1 to 83.6months).
Induction Therapy
Four patients died during induction in the ATRA-CHT group.
The causes of death were DS (n = 2), ischemic stroke (n = 1), and
bronchopneumonia (n = 1). All deaths were recorded in the initial
series,20 and no further deaths occurred in the second cohort of 110
patients enrolled in the postamendment period from March 2011
to January 2013. One hundred twenty-seven patients in the ATRA-
ATO arm and 136 patients in the ATRA-CHT arm were evaluable
for induction response. HCR was documented in 127 patients
(100%) and 132 patients (97%) in the ATRA-ATO and ATRA-CHT
arms, respectively (P = .12). For two patients who started induction
in the ATRA-ATO arm, the assigned treatment was terminated
early. For one of these patients, a protocol violation occurred (early
evaluation of bone marrow aspirate at day +13 with inappropriate
diagnosis of resistant disease). This patient was alive at 2 years
from diagnosis. In the other patient, treatment was permanently
withdrawn by the treating physician as a result of toxicity (QTc
prolongation and electrolyte abnormalities at day +3), and the
patient was lost to follow-up. In one patient in the ATRA-CHT
arm, treatment was discontinued as a result of an unknown reason,
and the patient was lost to follow-up.
Evaluable for induction
response
(n = 136)
Complete response
(n = 132)
Evaluable for PCR after
third consolidation
(n = 119)
PCR negative
(n = 117)
Excluded                                      (n = 10)
  Did not meet inclusion criteria  (n = 6)
  Did not receive allocated 
    treatment                                   (n = 4)
  Treatment refusal              (n = 2)
  Major protocol violation   (n = 2)
Discontinued intervention (n = 2)
 Toxicity                  (n = 1)
 Medical decision   (n = 1)
Discontinued intervention (n = 1) 
 Unknown reason
Evaluable for induction
response
(n = 127)
Complete response
(n = 127)
Evaluable for PCR after
third consolidation
(n = 115)
PCR negative
(n = 115)
Randomly assigned to
ATRA-ATO arm
(n = 129)
Randomly assigned to
ATRA-CHT arm
(n = 137)
Included in 
intent-to-treat analysis
(n = 266)
Randomly assigned
(N = 276)
Induction death
(n = 4)
NE for PCR after third
   consolidation
   Protocol violation           (n = 2)
   Treatment refusal           (n = 1)
   Toxicity                           (n = 4)
   Medical decision            (n = 1)
   Lost to follow-up            (n = 2)
   Missing data                   (n = 2)
(n = 12)
NE for PCR after third
   consolidation
  Lost to follow-up               (n = 4)
  Toxicity                               (n = 6)
  Unknown reason               (n = 1)
  Hepatitis reactivation        (n = 1)
  PCR not done                     (n = 1)
(n = 13)
Fig 1. Study enrollment, random assign-
ment, and retention. ATO, arsenic trioxide;
ATRA, all-trans-retinoic acid; CHT, chemo-
therapy; NE, not evaluable; PCR, polymerase
chain reaction.
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Leukocytosis greater than 10 3 109/L developed during in-
duction in 56 patients (43%) receiving ATRA-ATO and was suc-
cessfully managed in all patients with hydroxyurea as per protocol
recommendation. Moderate and severe DS (deﬁned as in Montesinos
et al24) occurred during induction in 16 patients (13%) and ﬁve
patients (4%) in the ATRA-ATO arm and in nine patients (7%) and
eight patients (6%) in the ATRA-CHTarm, respectively (P = .38), and
was fatal in two patients in the ATRA-CHTarm. In eight patients (four
patients in each arm), indeterminate DS (deﬁned according to Frankel
et al25) was reported.
Consolidation Therapy
Of 259 patients who proceeded to consolidation therapy, 234
patients (115 in the ATRA-ATO arm and 119 in the ATRA-CHT
arm) were evaluable for molecular response after the third con-
solidation cycle. Twelve of 127 patients in the ATRA-ATO arm
went off protocol before the bone marrow assessment after third
consolidation as a result of major protocol violation (n = 2),
consent withdrawal (n = 1), medical decision (n = 1), loss to
follow-up (n = 2), toxicity (n = 4), or missing data (n = 2). In the
ATRA-CHTarm, 13 of 132 patients did not undergo bone marrow
evaluation after third consolidation because of major protocol
violation (PCR not performed, n = 1), loss to follow-up (n = 4),
toxicity (n = 6), hepatitis reactivation (n = 1), or missing data (n = 1).
Six patients (one in the ATRA-ATO arm and ﬁve in the ATRA-CHT
arm) died in CR. The patient in the ATRA-ATO group died of
bronchopneumonia driven by H1N1 virus. Of the ﬁve deaths in the
ATRA-CHT group, one was caused by hemorrhagic shock, one by
pulmonary embolism, two by bronchopneumonia, and one by
secondary myelodysplastic syndrome.
Molecular evaluation of PML-RARA by RT-PCR after third
consolidation showed PCR negativity in all patients in the ATRA-
ATO arm, whereas two (1.7%) of 119 patients in the ATRA-CHT
arm tested positive by PCR and were considered as having mo-
lecular resistance. Of these, one patient was treated with ATO
salvage therapy followed by allogeneic stem-cell transplantation
and remained in second CR 14months after transplantation. In the
other patient, a second PCR test after the end of consolidation did
not conﬁrm PCR positivity. The patient was continued on ATRA
and low-dose CHT maintenance and remained in remission for
greater than 24 months.
Maintenance Therapy (ATRA-CHT Arm)
All 117 patients in the ATRA-CHT arm who completed
consolidation and tested RT-PCR negative for PML-RARA pro-
ceeded to maintenance. Excluding the nine patients who experi-
enced relapse during maintenance, 20 patients did not complete
maintenance as a result of toxicity (n = 4), treatment refusal (n = 3),
major protocol violation (n = 1), or other reasons (n = 12).
Toxicities
Hematologic and nonhematologic toxicities are listed in
Tables 2 and 3, respectively. A total of 95 serious adverse events
(SAEs) were reported in 65 patients. Of these, 43 and 52 SAEs were
reported in patients receiving ATRA-ATO and ATRA-CHT, re-
spectively. The complete list of detailed SAEs is reported in Ap-
pendix Table A1 (online only).
Hematologic toxicity. As shown in Table 2, a signiﬁcantly
higher number of patients in the ATRA-CHT arm compared with
the ATRA-ATO arm experienced grade 3 or 4 neutropenia and
thrombocytopenia lasting more than 15 days (P , .001). Episodes
of febrile neutropenia (including fever of unknown origin and
Table 1. Demographic, Clinical, and Laboratory Characteristics of the Eligible
Patients
Characteristic
ATRA-ATO
(n = 129)
ATRA-CHT
(n = 137) P
Median age, years (range) 46.6 (18.8-70.2) 46.6 (18-70.3) .84
Sex, No. (%) .45
Male 60 (46.5) 70 (51.1)
Female 69 (53.5) 67 (48.9)
Median WBC, 3 109/L (range) 1.4 (0.32-10) 1.5 (0.3-9.61) .83
Median platelets, 3 109/L (range) 36.5 (3-224) 31.5 (3-236) .19
Sanz risk, No. (%) .52
Low 57 (45.2) 55 (41.3)
Intermediate 69 (54.7) 78 (58.6)
PML-RARA isoform, No. (%) .35
Long 83 (68.6) 78 (62.9)
Short 38 (31.4) 46 (37.1)
Missing 8 (7) 13 (10)
FLT3-ITD, No. (%) .59
Mutated 26 (25.5) 22 (22.2)
Unmutated 76 (74.5) 77 (77.8)
Missing 27 (21) 38 (28)
Abbreviations: ATO, arsenic trioxide; ATRA, all-trans-retinoic acid; CHT, che-
motherapy; ITD, internal tandem duplication.
Table 2. Hematologic Toxicity
Toxicity and Treatment Arm
Induction First Consolidation Second Consolidation Third Consolidation
No. (%) P No. (%) P No. (%) P No. (%) P
Neutropenia (grade 3-4 lasting . 15 days) , .001 , .001 , .001 , .001
ATRA-ATO 61 (35) 8 (16) 7 (7) 5 (15)
ATRA-CHT 109 (64) 40 (67) 90 (92) 28 (85)
Thrombocytopenia (grade 3-4 lasting . 15 days) , .001 , .001 , .001 , .001
ATRA-ATO 74 (38) 6 (26) 6 (7) 8 (23)
ATRA-CHT 120 (62) 17 (74) 77 (93) 26 (76)
Infection and FUO , .001 .54 , .001 1.0
ATRA-ATO 30 (23) 10 (8) 4 (3) 2 (1.6)
ATRA-CHT 75 (55) 8 (6) 46 (38) 2 (1.7)
Abbreviations: ATO, arsenic trioxide; ATRA, all-trans-retinoic acid; CHT, chemotherapy; FUO, fever of unknown origin.
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documented infections counted together) were also signiﬁcantly
more frequent in the ATRA-CHTarm than in the ATRA-ATO arm.
In particular, in the ATRA-ATO and ATRA-CHT arms, 30 and 75
episodes were documented during the induction course (P, .001),
10 and eight occurred during the ﬁrst consolidation cycle (P = .54),
four and 46 occurred during the second consolidation cycle
(P, .001), and two and two occurred during the third consolidation
cycle (P = 1.0), respectively.
Other toxicities. Signiﬁcant elevation of liver function tests
(grade 3 or 4 according to National Cancer Institute Common
Terminology Criteria for Adverse Events) was more frequent in the
ATRA-ATO arm (44%) compared with the ATRA-CHT (3%) arm
across all treatment cycles (P , .001). Toxicity resolved in all
patients with temporary discontinuation of ATO and/or ATRA or
of low-dose CHT during maintenance (for patients in the ATRA-
CHT arm). QTc prolongation, deﬁned as QTc greater than 450
milliseconds for men and greater than 460 milliseconds for women
with correction calculated using the Framingham formula, was
observed in 15 patients (11%) in the ATRA-ATO arm and one
patient in the ATRA-CHT arm (P , .001) throughout the treat-
ment cycles. There were no cases of life-threatening cardiac ar-
rhythmias; however, ATO was permanently discontinued in one of
the 15 patients, and the patient went off protocol. Neurotoxicity
mainly consisting of reversible peripheral nerve neuropathy was
observed in a greater proportion of patients in the ATRA-ATO arm
and occurred during consolidation. Finally, GI toxicity and cardiac
function abnormalities were signiﬁcantly more frequent in the
ATRA-CHT arm (Table 3).
Outcomes
All outcome estimates calculated at 24 and 50 months are
listed in Table 4, whereas outcome curves are shown in Figure 2.
Primary end point. A total of 263 patients (127 and 136 in the
ATRA-ATO and ATRA-CHTarms, respectively) were evaluable for EFS
according to the intent-to-treat analysis. In theATRA-ATOgroup, 98.3%
of patients (95%CI, 95.9% to 100%) were event free at 24months from
random assignment, compared with 86.8% in the ATRA-CHT group
(95%CI, 81.1% to 92.8%; P, .001). At 50months, EFS estimates were
97.3% (95%CI, 94.3% to 100%) and 80.0% (95%CI, 72.9% to 88.0%)
in the ATRA-ATO and ATRA-CHT groups, respectively. Although 263
patients is not the full intent-to-treat complement for EFS evaluation, the
number of unevaluable patients was small.
The noninferiority analysis was carried out in 229 patients
with sufﬁcient follow-up (beyond 24 months). Of these patients,
Table 3. Nonhematologic Toxicity
Toxicity and Treatment Arm
Induction First Consolidation Second Consolidation Third Consolidation
No. (%) P No. (%) P No. (%) P No. (%) P
Hepatic toxicity (grade 3-4) , .001 .11 .49
ATRA-ATO 51 (40) 5 (4) 1 (0.8) 0
ATRA-CHT 4 (3) 1 (0.7) 0 0
QTc prolongation .0022 .11 .11 .23
ATRA-ATO 11 (8.5) 3 (2) 3 (2) 2 (1.5)
ATRA-CHT 1 (0.7) 0 0 0
Cardiac function (grade 3-4) .06
ATRA-ATO 0 0 0 0
ATRA-CHT 5 (3.7) 0 0 0
Neurotoxicity (all grades) .48 .02 .01 .006
ATRA-ATO 1 (0.7) 5 (4.2) 6 (5) 7 (5.9)
ATRA-CHT 0 0 0 0
GI toxicity (grade 3-4) , .001 1.0 .03 1.0
ATRA-ATO 3 (2) 0 0 0
ATRA-CHT 25 (18.2) 1 (0.8) 6 (4.9) 0
Hypercholesterolemia .55 .13 .14 .27
ATRA-ATO 14 (10) 19 (16) 19 (16) 16 (14)
ATRA-CHT 12 (8.7) 12 (9.6) 12 (9.7) 11 (9)
Hypertriglyceridemia 0.76 .49 .12 .5
ATRA-ATO 29 (22) 22 (18.4) 17 (14.4) 16 (14)
ATRA-CHT 29 (22) 19 (15.2) 10 (8) 13 (11)
Abbreviations: ATO, arsenic trioxide; ATRA, all-trans-retinoic acid; CHT, chemotherapy.
Table 4. Outcome Results
Outcome and
Treatment Arm
Probability, % (95% CI)
P24 Months 50 Months
Overall survival .0073
ATRA-ATO 99.2 (97.7 to 100) 99.2 (97.7 to 100)
ATRA-CHT 94.8 (91.1 to 98.6) 92.6 (87.9 to 97.5)
Event-free survival , .001
ATRA-ATO 98.3 (95.9 to 100) 97.3 (94.3 to 100)
ATRA-CHT 86.8 (81.1 to 92.8) 80.0 (72.9 to 88.0)
Disease-free
survival
, .001
ATRA-ATO 98.3 (95.9 to 100) 97.3 (94.3 to 100)
ATRA-CHT 89.4 (84.1 to 95.0) 82.6 (75.6 to 90.3)
Cumulative incidence
of relapse
.0013*
ATRA-ATO 0.9 (0 to 2.7) 1.9 (0.0 to 4.5)
ATRA-CHT 8.2 (3.3 to 13.2) 13.9 (7.1 to 20.6)
Abbreviations: ATO, arsenic trioxide; ATRA, all-trans-retinoic acid; CHT,
chemotherapy.
*Gray test.
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98.15% in the ATRA-ATO group (106 of 108 patients) were alive
and event free at 24 months, compared with 85.95% of patients
in the ATRA-CHT group (104 of 121 patients), with a difference in
the EFS rates at 2 years of 12.2% (95% CI, 4.3% to 20.1%); because
the lower bound of the 95% CI for this difference was $ 5%, the
noninferiority of ATRA-ATO was conﬁrmed (P , .001).
Seventeen patients experienced relapse during follow-up. Of
these, two relapses occurred in the ATRA-ATO arm at 22 and
27 months, and 15 occurred in the ATRA-CHT arm at a median
time of 14.0 months (range, 2.5 to 39.8 months). In four patients,
relapse was detected at the molecular level before hematologic
relapse, leading to administration of pre-emptive salvage therapy.
Two patients in the ATRA-CHT arm and none in the ATRA-ATO
arm developed a therapy-related myeloid neoplasm. Of these, one
patient with therapy-related myelodysplastic syndrome died as
a result of disease progression, whereas in the other patient,
a therapy-related acute myeloid leukemia was diagnosed, and the
patient remained alive in CR 14 months after undergoing allo-
geneic stem-cell transplantation.
Secondary end points. The 24- and 50-month OS, DFS, and
CIR rates for patients in the two arms are listed in Table 4. The
results of the kinetics of molecular response and impact of FLT3
status will be reported in a separate publication.
Regarding QoL, the results of the current extended series
broadly conﬁrm previously reported ﬁndings26 on the beneﬁts of
ATRA-ATO versus ATRA-CHT after induction therapy. The pre-
vious main observation that fatigue severity (as measured by the
European Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire C30) was signiﬁcantly lower in the
group treated with ATRA-ATO versus ATRA-CHT after induction
therapy (P = .034)26 was fully conﬁrmed in this larger patient
population (P = .008). A long-term QoL analysis has been planned,
and full details will be reported separately.
DISCUSSION
This study shows that, compared with ATRA-CHT, the ATRA-ATO
combination signiﬁcantly improved both survival and relapse risk
in patients with newly diagnosed, low- or intermediate-risk APL.
Compared with our previous report in which no signiﬁcant dif-
ferences in DFS and CIR rates were found, we report here that the
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Fig 2. Outcome estimates. (A) Overall survival. (B) Event-free survival. (C) Disease-free survival. (D) Relapse. ATO, arsenic trioxide; ATRA, all-trans-retinoic acid;
CHT, chemotherapy.
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CHT-free approach based on ATRA-ATO resulted in higher an-
tileukemic efﬁcacy. In addition, the present analysis conducted in
a substantially extended cohort of patients with prolonged follow-
up revealed signiﬁcantly improved differences in all other analyzed
outcomes (EFS, OS, and DFS) compared with the initial report.20
These data indicate that the advantage of ATRA-ATO over ATRA-
CHT increases over time and that the inclusion of ATO in the
treatment of low- or intermediate-risk APL not only reduces
mortality and hematologic toxicity, but also results in improved
and sustained antileukemic activity. Neither additional fatal events
nor further relapses were recorded in patients randomly assigned
to ATRA-ATO in this extended cohort. By contrast, new relapses,
two instances of molecular resistance (ie, testing PCR positive after
third consolidation), and two therapy-related myeloid neoplasms
were observed in the group of patients receiving ATRA-CHT.
A recent study conducted in the United Kingdom by the
National Cancer Research Institute (NCRI) reported similar
results in terms of EFS and relapse rate, with patients treated with
ATRA-ATO showing signiﬁcantly better outcomes.21 At variance
from our study, the NCRI trial used an ATO schedule consisting
of two or three weekly administrations at increased doses and
included no maintenance in the ATRA-CHT arm (which was
otherwise derived from the same ATRA and idarubicin [AIDA]
protocol used in our study). Furthermore, the study included
patients with high-risk disease, for whom a provisionwas made to
use one or two 6 mg/m2 doses of gemtuzumab ozogamicin during
the ﬁrst 4 days of induction. This important study independently
conﬁrmed the advantage of including ATO in ﬁrst-line man-
agement of APL, suggesting that the beneﬁt is also observed in
high-risk patients. In this respect, however, it should be noted
that a total of 57 patients with high-risk disease were included in
the comparison and that the efﬁcacy of ATO in this patient subset
may be difﬁcult to analyze given the addition of a potent anti-APL
agent such as gemtuzumab ozogamicin.21 A randomized trial
comparing ATRA-ATO to the AIDA2000 protocol5 and involving
several European cooperative groups will be started soon to
further investigate this issue.
The toxicity proﬁles in the current study were comparable to
those observed for the two cohorts in the original series. For
patients receiving ATRA-ATO, adverse effects mainly consisted
of frequent increase of liver enzymes, QTc prolongation, and
hyperleukocytosis. In almost all patients, this toxicity was re-
versible and manageable with temporary drug interruption and
dose adjustments as per protocol recommendations, including the
addition of hydroxyurea (the only cytotoxic agent allowed for the
control of hyperleukocytosis). The study from the United King-
dom21 reported similar toxicities for patients in the ATO group in
terms of DS and cardiac adverse effects, but a lower incidence of
grade 3 or 4 hepatic toxicity, probably as a result of the different
schedule. Regarding medium- and long-term toxicity, the absence
of secondary therapy-related myeloid neoplasms at the extended
follow-up in the ATRA-ATO cohort also represents a major im-
provement in the treatment of a disease where high cure rates
are achieved.
In conclusion, in line with results of pilot studies18,19 and
those of the recent randomized NCRI trial,21 our results support
the use of ATRA-ATO in patients with newly diagnosed APL and
point to this strategy as the new standard of care for low- or
intermediate-risk patients. Studies exploring the role of ATRA-
ATO are warranted in other APL subsets including high-risk,
pediatric, and elderly patients.
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Udine (Renato Fanin, MD); Dipartimento di Scienze Biologiche, Medicina Interna 2, Ospedale S. Luigi Gonzaga, Orbassano
(Daniela Cilloni, MD); Dipartimento Oncologico, Ospedale S. Maria delle Croci, Ravenna (Eliana Zuffa, MD); Medicina Interna I,
Ospedale di Circolo, Varese (Leonardo Campiotti, MD); Dipartimento di Ematologia e Trapianto di Midollo, Istituto Scientiﬁco
San Raffaele, Milan (Fabio Ciceri, MD); Divisione di Ematologia TERE, Ospedale Cardarelli, Napoli (Olimpia Finizio, MD) in Italy.
Klinikum Nord Nu¨rnberg, Nu¨rnberg (Kerstin Scha¨fer-Eckart, MD); Robert Bosch Krankenhaus Stuttgart, Stuttgart (Walter
Aulitzky, MD); Friedrich-Alexander-Universita¨t Erlangen, Erlangen (Stefan Krause, MD); Ev. Diakonie-Krankenhaus gGmbH
Bremen, Bremen (Johannes Kullmer, MD); Klinikum der Johannes Gutenberg Universita¨t Mainz, Mainz (Markus Radsak,
MD); Universita¨tsklinikum Essen, Essen (Ulrich Du¨hrsen, MD); Klinikum rechts der Isar, Mu¨nchen, Mu¨nchen (Katharina
Go¨tze, MD); Universita¨tsmedizin Go¨ttingen, Go¨ttingen (Gerald Wulf, MD); Helios Klinikum Wuppertal, Wuppertal (Aruna
Raghavachar, MD); Caritas-Krankenhaus Lebach, Lebach (Stephan Kremers, MD); Landeskrankenhaus Salzburg, Salzburg
(Richard Greil, MD); Charite`-Campus Virchow Klinikum Berlin, Berlin (Jo¨rg Westermann, MD); Universita¨tsklinikum Bonn,
Bonn (Marie von Lilienfeld-Toal, MD) in Germany.
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Table A1. Hematologic Toxicity
Randomly
Assigned
Treatment UPN System, Organ, Class Preferred Term Drug 1 Relationship 1 Drug 2 Relationship 2 Outcome
ATRA-ATO 1 Investigations ECG QT prolonged ATO Related ATRA Related Recovered
ATRA-ATO 2 Infections Pneumonia ATO Related ATRA Related Recovered
ATRA-ATO 2 Respiratory, thoracic,
and mediastinal
disorders
Respiratory failure ATO Related ATRA Related Unchanged
ATRA-ATO 3 Investigations ALT increased ATO Related ATRA Related Recovered
ATRA-ATO 4 Respiratory, thoracic,
and mediastinal
disorders
APL differentiation
syndrome
ATO Related ATRA Related Recovered
ATRA-ATO 5 Nervous system
disorders
Cerebrovascular
accident
ATO Related ATRA Related Recovered
ATRA-ATO 6 Respiratory, thoracic,
and mediastinal
disorders
Dyspnea ATO Unrelated — — Recovered
ATRA-ATO 7 Respiratory, thoracic,
and mediastinal
disorders
Respiratory failure ATO Unrelated — — Recovered
ATRA-ATO 8 Cardiac disorders Pericarditis ATO Unrelated ATRA Unrelated Recovered
ATRA-ATO 9 Injury poisoning and
procedural
complications
Maternal exposure
before pregnancy
ATO Unrelated — — Recovered
ATRA-ATO 10 Hepatobiliary disorders Hepatotoxicity ATO Related ATRA Related Recovered
ATRA-ATO 11 Nervous system
disorders
Cerebral hemorrhage ATO Related ATRA Related —
ATRA-ATO 12 Vascular disorders Intracranial aneurysm ATO Unrelated ATRA Unrelated Unchanged
ATRA-ATO 13 Investigations ALT increase ATO Related ATRA Related Recovered
ATRA-ATO 13 Investigations AST increase ATO Related ATRA Related Recovered
ATRA-ATO 14 GI disorders Dyspepsia ATO Related — — Recovered
ATRA-ATO 14 Respiratory, thoracic,
and mediastinal
disorders
APL differentiation
syndrome
ATO Not assessable — — Recovered
ATRA-ATO 15 Eye disorders Diplopia ATO Not assessable ATRA Not assessable Recovered
ATRA-ATO 16 Psychiatric disorders Confusional state ATO Unrelated — — Recovered
ATRA-ATO 17 Hepatobiliary disorders Hypertransaminasemia ATO Related ATRA Related Recovered
ATRA-ATO 18 Infections Catheter site infection ATO Unrelated — — Recovered
ATRA-ATO 19 Infections Pneumonia ATO Unrelated ATRA Unrelated Recovered
ATRA-ATO 20 General disorders and
administration site
conditions
Pyrexia ATO Unrelated ATRA Unrelated —
ATRA-ATO 21 Hepatobiliary disorders Hepatic failure ATO Related ATRA Related Recovered
ATRA-ATO 21 Respiratory, thoracic,
and mediastinal
disorders
APL differentiation
syndrome
ATO Related ATRA Related Recovered
ATRA-ATO 22 Infections Herpes zoster — Related — Related Recovered
ATRA-ATO 22 Nervous system
disorders
Hydrocephalus ATO Related ATRA Related Unchanged
ATRA-ATO 22 Skin and subcutaneous
tissue disorders
Leukocytoclastic
vasculitis
ATO Unrelated ATRA Unrelated Recovered
ATRA-ATO 23 Respiratory, thoracic,
and mediastinal
disorders
Pneumonia ATO Unrelated ATRA Unrelated Fatal
ATRA-ATO 24 Respiratory, thoracic,
and mediastinal
disorders
Dyspnea ATO Unrelated — — Recovered
ATRA-ATO 25 Nervous system
disorders
Depression — — — — Recovered
ATRA-ATO 26 Respiratory, thoracic,
and mediastinal
disorders
Retinoic acid syndrome ATO Related ATRA Related Recovered
ATRA-ATO 27 Cardiac disorders Syncope ATO Unrelated ATRA Unrelated Recovered
ATRA-ATO 27 Hepatobiliary disorders Cholelithiasis ATO Unrelated ATRA Related Recovered
ATRA-ATO 27 Investigations Hepatic enzyme
increased
ATO Related ATRA Related Recovered
ATRA-ATO 27 Musculoskeletal and
connective tissue
disorders
Fracture ATO Unrelated ATRA Unrelated Recovered
ATRA-ATO 28 Infections Catheter site infection ATO Unrelated — — Recovered
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Table A1. Hematologic Toxicity (continued)
Randomly
Assigned
Treatment UPN System, Organ, Class Preferred Term Drug 1 Relationship 1 Drug 2 Relationship 2 Outcome
ATRA-ATO 29 Investigations C-reactive protein
increased
ATO Related — — Recovered
ATRA-ATO 29 Respiratory, thoracic,
and mediastinal
disorders
Dyspnea ATO Related — — Recovered
ATRA-ATO 30 Infections Febrile infection ATO Related ATRA Related Recovered
ATRA-ATO 30 Reproductive system
and breast disorders
Endometriosis ATO Unrelated ATRA Unrelated Recovered
ATRA-ATO 31 Cardiac disorders Acute myocardial
infarction
ATO Unrelated ATRA Unrelated Recovered
ATRA-ATO 32 Investigations ECG QT prolonged ATO Related — — Recovered
ATRA-CHT 33 Respiratory, thoracic,
and mediastinal
disorders
Acute respiratory
distress syndrome
IDA Related ATRA Related Fatal
ATRA-CHT 34 Cardiac disorders Myocardial ischemia IDA Related ATRA Related Recovered
ATRA-CHT 35 Respiratory, thoracic,
and mediastinal
disorders
Respiratory failure IDA Related ATRA Related Fatal
ATRA-CHT 35 Respiratory, thoracic,
and mediastinal
disorders
Retinoic acid syndrome IDA Related ATRA Related Fatal
ATRA-CHT 36 Cardiac disorders Acute myocardial
infarction
IDA Unrelated ATRA Unrelated Recovered
ATRA-CHT 37 Investigations Aminotransferases
increased
IDA Unrelated ATRA Unrelated Unchanged
ATRA-CHT 38 Blood and lymphatic
system disorders
Febrile neutropenia MTX Related ATRA Related Recovered
ATRA-CHT 39 GI disorders Pancreatitis acute ATRA Unrelated — — Recovered
ATRA-CHT 40 Nervous system
disorders
Ischemic stroke IDA Related ATRA Related Fatal
ATRA-CHT 41 Cardiac disorders Pericarditis IDA Related ATRA Related Improved
ATRA-CHT 42 Cardiac disorders Cardiac failure IDA Related ATRA Related Recovered
ATRA-CHT 43 General disorders and
administration site
conditions
Pyrexia MTX Related ATRA Related Recovered
ATRA-CHT 44 Blood and lymphatic
system disorders
Febrile neutropenia MTX Related ATRA Related —
ATRA-CHT 45 Blood and lymphatic
system disorders
Bone marrow failure MTX Related ATRA Related Improved
ATRA-CHT 46 Respiratory, thoracic,
and mediastinal
disorders
Pulmonary embolism — — — Not assessable Improved
ATRA-CHT 46 Respiratory, thoracic,
and mediastinal
disorders
Retinoic acid syndrome — — ATRA Related Improved
ATRA-CHT 46 Vascular disorders Shock hemorrhagic IDA Unrelated ATRA Unrelated Fatal
ATRA-CHT 47 Infections Bronchopneumonia — — ATRA Related Fatal
ATRA-CHT 48 Vascular disorders Thrombosis IDA Related ATRA Related Recovered
ATRA-CHT 48 Infections Bronchopneumonia MTX Related — — Fatal
ATRA-CHT 49 Blood and lymphatic
system disorders
Febrile neutropenia IDA Related ATRA Related Recovered
ATRA-CHT 50 Blood and lymphatic
system disorders
Neutropenia MTX Related ATRA Related Recovered
ATRA-CHT 50 Infections Pneumonia MTX Related ATRA Related Recovered
ATRA-CHT 51 General disorders and
administration site
conditions
Mucosal inﬂammation IDA Related ATRA Related Recovered
ATRA-CHT 51 Vascular disorders Pulmonary embolism — Unrelated — — Fatal
ATRA-CHT 52 GI disorders Inguinal hernia MP Unrelated MTX Unrelated Recovered
ATRA-CHT 53 Blood and lymphatic
system disorders
Febrile neutropenia MTX Related ATRA Related Improved
ATRA-CHT 53 GI disorders Anal hemorrhage MTX Related ATRA Related Recovered
ATRA-CHT 53 Injury poisoning and
procedural
complications
Maternal exposures
before pregnancy
ATRA Unrelated MP Unrelated Recovered
ATRA-CHT 54 Blood and lymphatic
system disorders
Febrile neutropenia — Related — — Recovered
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Table A1. Hematologic Toxicity (continued)
Randomly
Assigned
Treatment UPN System, Organ, Class Preferred Term Drug 1 Relationship 1 Drug 2 Relationship 2 Outcome
ATRA-CHT 54 Blood and lymphatic
system disorders
Febrile neutropenia IDA — ATRA — Recovered
ATRA-CHT 54 Vascular disorders Extradural hematoma IDA Unrelated ATRA Unrelated Improved
ATRA-CHT 55 Respiratory, thoracic,
and mediastinal
disorders
Retinoic acid syndrome IDA Related ATRA Related Improved
ATRA-CHT 56 Infections Urinary tract infection IDA Unrelated ATRA Unrelated Recovered
ATRA-CHT 57 Blood and lymphatic
system disorders
Febrile neutropenia MTX Related ATRA Related Recovered
ATRA-CHT 58 General disorders and
administration site
conditions
Pyrexia MP Related — — Recovered
ATRA-CHT 58 Infections Bacteremia IDA Related ATRA Related Recovered
ATRA-CHT 58 Infections Infection MP Related — — Recovered
ATRA-CHT 58 Infections Infection MTX Related ATRA Related Recovered
ATRA-CHT 59 Cardiac disorders Ejection fraction
decreased
MP + MTX Unrelated ATRA Unrelated Unchanged
ATRA-CHT 60 Infections Sepsis IDA Related ATRA Related Recovered
ATRA-CHT 61 Cardiac disorders Pericarditis IDA Related — — Unchanged
ATRA-CHT 61 General disorders and
administration site
conditions
Mucosal inﬂammation MTX Related ATRA Related Recovered
ATRA-CHT 61 Respiratory, thoracic,
and mediastinal
disorders
Respiratory failure — — — — Recovered
ATRA-CHT 62 GI disorders Diarrhea ATRA Unrelated — — Recovered
ATRA-CHT 62 GI disorders Emesis ATRA Unrelated — — Recovered
ATRA-CHT 63 General disorders and
administration site
conditions
Fever in aplasia IDA + MTX Related ATRA Related Recovered
ATRA-CHT 64 Infections Sepsis IDA Unrelated ATRA Unrelated Recovered
ATRA-CHT 64 Investigations Hyperglycemia MTX, MP Unrelated ATRA Unrelated Recovered
ATRA-CHT 64 Blood and lymphatic
system disorders
Febrile neutropenia MTX Related ATRA Related Recovered
ATRA-CHT 65 Cardiac disorders Tachyarrhythmia Prednisone Unrelated ATRA Unrelated Recovered
ATRA-CHT 65 Infections Pneumonia Prednisone Related ATRA Related Recovered
Abbreviations: APL, acute promyelocytic leukemia; ATO, arsenic trioxide; ATRA, all-trans-retinoic acid; CHT, chemotherapy; IDA, idarubicin; MP, mercaptopurine; MTX,
methotrexate; UPN, unique patient number.
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